Who needs ventricular stimulation studies?
Two randomised studies reported in the New England J7ournal of Medicine have cast doubt on the value of ventricular stimulation studies in the assessment of antiarrhythmic drug therapy in patients with symptomatic sustained ventricular arrhythmias. In the study by Steinbeck and coworkers 115 patients with inducible ventricular arrhythmias were assigned to treatment with electrophysiologically guided drug therapy or with empirical metoprolol.' During a mean follow up of 23 months the incidence of recurrent arrhythmia and sudden death was almost identical in the two groups. Steinbeck et al concluded that electrophysiologically guided drug therapy did not improve the overall outcome of patients with sustained ventricular arrhythmias. In the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) study 486 patients with both inducible ventricular arrhythmias and frequent ventricular extrasystoles during Holter monitoring were randomly assigned to antiarrhythmic therapy guided by either electrophysiological study or by Holter monitoring.2' Over a 6 year follow up there was no significant difference between the two study groups in terms of recurrence of arrhythmia, sudden death, or total mortality. The ESVEM group recommended that treatment with sotalol (the most effective drug in the trial) and assessment of its potential efficacy by Holter Widespread implantation is now a practical option and cost restraints have come to the fore. Selection of patients for device therapy is increasingly based on costbenefit issues, with those at highest risk from sudden death having the most to gain.
A large body of information is available on the prognostic value of ventricular stimulation studies7 11-13 and together with the clinical history and assessment of ventricular function, such studies are an integral part of the assessment of risk in patients with sustained ventricular arrhythmias. In many centres the decision to implant a device is based on the inducibility of a ventricular arrhythmia at baseline or in the presence of a single antiarrhythmic drug.'4 Usually the response to a class 1 agent (often intravenous procainamide) is used for this purpose but there is evidence that other drugs, including amiodarone, may be as useful in such tests. The likelihood of tachycardia induction is higher after amiodarone (approximately 80% of patients) than after administration of class 1 agents and the effect of amiodarone on the rate of the induced arrhythmia provides the principal means of prognostic assessment. '2 15 Although the ESVEM study showed that there was no difference in terms of arrhythmia recurrence between drug therapy selected by invasive and non-invasive techniques (they seemed equally ineffective) the study was not designed to compare the prognostic value of the two techniques in terms of mortality and did not have the power to do so. There is considerably less information on the prognostic power of Holter monitoring in the setting of recurrent sustained ventricular arrhythmias than on that of programmed electrical stimulation. Newer noninvasive means of risk assessment (heart rate variability, signal averaged electrocardiography) have shown promise in patients assessed after infarction'6 but have yet to be fully evaluated in patients with recurrent ventricular arrhythmias. Consequently the suggestion that Holter assessment of drug therapy is a reasonable initial strategy in patients with sustained ventricular arrhythmias cannot be supported.
In summary, it is clear that the issues concerning management of sustained ventricular arrhythmias have changed since the design of the ESVEM study in the middle 1980s. There has been a dramatic trend away from antiarrhythmic drugs and towards device therapy.
The priority now is to be able to stratify patients with ventricular arrhythmias prognostically so as to determine those likely to benefit most from a limited resource. At present programmed electrical stimulation of the ventricle together with evaluation of the clinical history and assessment of ventricular function is the best way to do this. 
